Our Keynote prostate cancer clinical trials are studying pembrolizumab to see if it may help patients with prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Pembrolizumab is an investigational immunotherapy that targets the PD-1 pathway.
Pembrolizumab has been FDA-approved for use in certain types of cancer.
Clinical trials for prostate cancer are underway and currently enrolling patients. If you have patients with prostate cancer, you may want to consider a Keynote trial. To see if your patients qualify for one of these trials, contact our clinical trial information center at 1-888-577-8839. If you are interested in partnering with us as an investigator, call 1-800-290-4339.
|Trial Description||Keynote Trial||Condition||Phase||Status|
|Study of Pembrolizumab Combination Therapies in Metastatic Castration-Resistant Prostate Cancer||365||Metastatic Castration-Resistant Prostate Cancer||Phase 1||Recruiting|
|Study of Pembrolizumab in Participants With Metastatic Castration-Resistant Prostate Cancer||199||Metastatic Castration-resistant Prostate Cancer||Phase 2||Active, not recruiting|
|Study of Pembrolizumab Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer||641||Prostatic Neoplasms||Phase 3||Not yet recruiting|
|Study of Pembrolizumab Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer||921||Prostatic Neoplasms||Phase 3||Not yet recruiting|